Table 1.
Association of MPO+ and CD8+ cell infiltration with clinical-pathological features in 1,162 CRC
| MPO low CD8 low |
MPO high CD8 low |
MPO low CD8 high |
MPO high CD8 high |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Characteristics | n = 790 | (68 %) | n = 117 | (10 %) | n = 206 | (18 %) | n = 49 | (4 %) | p-value* | |
| Age | years (mean) | 70 | 71 | 69 | 72 | 0.656 | ||||
| Gender | Female | 396 | (50.1) | 64 | (54.7) | 122 | (59.2) | 25 | (51.0) | 0.047 |
| Male | 394 | (49.9) | 53 | (45.3) | 84 | (40.8) | 24 | (49.0) | ||
| Tumor location | Left-sided | 516 | (65.3) | 83 | (70.9) | 124 | (60.2) | 25 | (51.0) | 0.28 |
| Right-sided | 264 | (33.4) | 33 | (28.2) | 81 | (39.3) | 24 | (49.0) | ||
| Histologic subtype | Mucinous | 66 | (8.4) | 11 | (9.4) | 11 | (5.3) | 3 | (6.1) | 0.395 |
| Non-mucinous | 724 | (91.6) | 106 | (90.6) | 195 | (94.7) | 46 | (93.9) | ||
| pT stage | pT1–2 | 124 | (15.7) | 33 | (28.2) | 57 | (27.7) | 12 | (24.5) | <0.0001 |
| pT3–4 | 649 | (82.2) | 83 | (70.9) | 141 | (68.4) | 37 | (75.5) | ||
| pN stage | pN0 | 376 | (47.6) | 54 | (46.2) | 133 | (64.6) | 40 | (81.6) | <0.0001 |
| pN1–2 | 383 | (50.4) | 59 | (50.4) | 64 | (31.1) | 9 | (18.4) | ||
| Tumor grade | G1–2 | 686 | (86.8) | 101 | (86.3) | 170 | (82.5) | 36 | (73.5) | 0.12 |
| G3 | 89 | (11.3) | 14 | (12.0) | 28 | (13.6) | 12 | (24.5) | ||
| Vascular invasion | Absent | 550 | (69.6) | 85 | (72.6) | 155 | (75.2) | 40 | (81.6) | 0.023 |
| Present | 225 | (28.5) | 30 | (25.6) | 43 | (20.9) | 8 | (16.3) | ||
| Tumor border | Pushing | 261 | (33.0) | 40 | (34.2) | 100 | (48.5) | 29 | (51.2) | <0.0001 |
| Infiltrating | 513 | (64.9) | 75 | (64.1) | 98 | (47.6) | 19 | (38.8) | ||
| PTL inflammation | Absent | 633 | (80.1) | 94 | (80.3) | 149 | (72.3) | 29 | (59.2) | 0.018 |
| Present | 143 | (18.1) | 21 | (17.9) | 49 | (23.8) | 19 | (38.8) | ||
| Local recurrence | Absent | 144 | (18.2) | 33 | (28.2) | 50 | (24.3) | 15 | (30.6) | 0.0003 |
| Present | 131 | (16.6) | 18 | (15.4) | 18 | (8.7) | 3 | (6.1) | ||
| Distant metastasis | Absent | 219 | (27.7) | 43 | (36.8) | 62 | (30.1) | 19 | (38.8) | 0.011 |
| Present | 60 | (7.6) | 8 | (6.8) | 7 | (3.4) | 0 | (0.0) | ||
| Microsatellite stability | Deficient | 120 | (15.2) | 17 | (14.5) | 34 | (16.5) | 16 | (32.7) | 0.256 |
| Proficient | 670 | (84.8) | 100 | (85.5) | 172 | (83.5) | 33 | (67.3) | ||
| 5-year survival rate | (95%CI) | 51.3% | (47.6–55.0) | 69% | (60.4–78.9) | 71% | (64.7–78.0) | 64.3 | (51.2–80.8) | <0.0001 |
*
Correlation between the MPOlow / CD8low subgroup with the other 3 subgroups. Percentage may not add to 100% due to missing values of same variables.